Britannia Life Sciences Inc.
BLAB
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -5.39% | -1.77% | 6.66% | 16.02% | 10.94% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -5.39% | -1.77% | 6.66% | 16.02% | 10.94% |
| Cost of Revenue | 31.94% | 38.78% | 51.65% | 51.10% | 8.90% |
| Gross Profit | -21.17% | -17.42% | -9.80% | 2.68% | 11.83% |
| SG&A Expenses | -19.01% | -11.77% | 6.34% | -4.62% | -12.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.88% | 6.13% | 21.97% | 13.48% | -6.08% |
| Operating Income | -28.20% | -30.81% | -46.38% | 30.21% | 1,212.02% |
| Income Before Tax | -491.58% | -510.79% | -323.32% | -173.91% | 572.85% |
| Income Tax Expenses | -473.98% | -384.56% | -448.86% | -323.53% | -81.39% |
| Earnings from Continuing Operations | -492.13% | -516.62% | -319.86% | -173.17% | 15,636.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -206.00% | 43.87% | 71.95% | 51.71% | 81.22% |
| Net Income | -566.69% | -751.27% | -456.02% | -191.03% | 273.57% |
| EBIT | -28.20% | -30.81% | -46.38% | 30.21% | 1,212.02% |
| EBITDA | -34.25% | -32.70% | -42.93% | 26.89% | 405.94% |
| EPS Basic | -565.38% | -740.38% | -451.43% | -168.13% | 85.71% |
| Normalized Basic EPS | -1,227.27% | -1,362.50% | -1,660.00% | -206.08% | -92.25% |
| EPS Diluted | -565.38% | -740.38% | -451.43% | -168.13% | 85.71% |
| Normalized Diluted EPS | -1,227.27% | -1,362.50% | -1,660.00% | -206.08% | -92.25% |
| Average Basic Shares Outstanding | 0.00% | 0.01% | 0.01% | 8.86% | 8.14% |
| Average Diluted Shares Outstanding | 0.00% | 0.01% | 0.01% | 8.86% | 8.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |